3 not yet recruiting, 2 recruiting, 1 completed, 1 enrolling by invitation. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 3, Recruiting 2, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 3 | Not yet recruiting 2, Recruiting 1 |
Follow Alzheimer s Disease: new trials by email Literature Review of Alzheimer s Disease trials Research Report on Alzheimer s Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response Lithium orotate, Matched Placebo (Capsules) - Alzheimer s Disease | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 40 | 2026-12-01 | 2026-10-07 |
| A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD) Gut-X-001 + Placebo capsule, Gut-X-001, Placebo - Alzheimer s Disease | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 120 | 2026-08-01 | 2026-06-11 |
| Low-Dose Radiotherapy for Alzheimer's Disease Low Dose Radiation Therapy - Alzheimer Dementia, Dementia | Phase 1 / Phase 2 | Recruiting | Evan Thomas | 50 | 2026-07-15 | 2026-07-09 |
| Fisetin in Mild Alzheimer's Disease Fisetin - Alzheimer s Disease, Alzheimer Dementia | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 5 | 2026-01-27 | 2026-08-20 |
| Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia intermittent theta burst stimulation (iTBS), Methylphenidate (MPH) - Alzheimer s Disease, Alzheimer Dementia (AD) | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 12 | 2026-01-01 | 2025-12-12 |
| TSPO Modulation in AD XBD173 - Alzheimer s Disease | Phase 2 | Enrolling by invitation | Imperial College London | 51 | 2025-08-08 | 2025-10-01 |
Alzheimer Disease (4) · Dementia (2) · Lethargy (1) · Neurocognitive Disorders (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Mental Disorders (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Tauopathies (4) · Neurocognitive Disorders (3) · Dementia (2) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Capsules (1) · Methylphenidate (1) · N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide (1) · Radiotherapy (1) · Terazosin (1) · fisetin (1) · lithium orotate (1)
Sunnybrook Health Sciences Centre (2) · Beijing Tiantan Hospital (1) · Evan Thomas (1) · Imperial College London (1) · Johns Hopkins University (1) · Qiang Zhang (1)
Canada (2) · United States (2) · United Kingdom (1)
Christopher Morrow, MD, MHS (1) · David Owen (1) · Evan Thomas, MD, PhD (1) · Krista Lanctot, PhD (1) · Qiang Zhang, MD (1)